胃癌患者手术前后血清CA724和CA50水平及临床意义

目的:研究血清糖链抗原(CA724)和糖链抗原(CA50)在胃癌患者手术前后的水平变化及临床意义。方法:胃癌患者33例,良性胃疾病患者31例,在33例胃癌患者中有6例复发转移,采用免疫放射分析法(IRMA)分别检测了空腹血清CA724和CA50水平。结果:胃癌组血清CA724和CA50水平分别为21.7±44.6U/ml,27.8±37.5U/ml,胃良性疾病组血清CA724和CA50水平分别为2.98±1.64U/ml,6.78±7.45U/ml,差异显著(P<0.01)。胃癌患者术前组血清CA724、CA50水平分别为21.7±44.6U/ml,27.8±37.5U/ml高于术后14.3±26.6U/ml,22.5±31.4U/ml,差异显著(P<0.01)和(P<0.05)。胃癌患者有淋巴结转移组血清CA724、CA50水平分别为27.3±64.5U/ml,30.6±48.8U/ml,高于无淋巴结转移组17.4±30.8U/ml,19.9±27.3U/ml,差异显著(P<0.01)。结论:手术切除肿瘤特别是行根治性切除术后,血清CA724水平显著降低。动态观察CA724、CA50水平及其变化,表明CA724、CA50水平与肿瘤的浸润及转移过程密切相关,胃癌患者手术前后的测定对有无复发转移是一项重要的判断指标。

Detection of serum CA724 and CA50 in pre-operation and post-operation stomach cancer patients

Objective:To evaluate the clinical usefulness of serum CA724 and CA50 in diagnosising and monitoring gastric cancer. Methods: Immunoradiometricassay(IRMA) was used to detect the content of serum CA724 and CA50 in 33 patients with gastric cancer(6 cases with tumor metastasis) and 31 control patients with benign stomach diseases. Results: The content of CA724 and CA50 in cancer group (21.7±44.6U/ml,27.8±37.5U/ml,respectively) was higher than that in benign disease group(2.98±1.64U/ml,6.78±7.45U/ml,respectively,P<0.01) and that in group after resection (14.3±26.6U/ml,P<0.01, 22.5±31.4U/ml,P<0.05,repectively,P<0.01).Conclusion: Radical resection can reduce the content of CA724 and CA50 in patients with gastric cancer. The content of the serum CA724 and CA50 is closely related to tumor invasion and metastasis. The assay of CA724 and CA50 in serum may be very useful to the diagnosis and prognosis of the gastris cancer.